Hyoeun Lee

Hyoeun Lee

Auto-generated profile, based on publicly available information

Hyoeun Lee

Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2019 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
HLHyoeun Lee
Hyoeun Lee
HSHong Ji Song
Hong Ji Song
YPYu-Jin Paek
Yu-Jin Paek
KPKyung-Hee Park
Kyung-Hee Park
HNHye-Mi Noh
Hye-Mi Noh
YSYoung-Gyun Seo
Young-Gyun Seo
Background: This study evaluated factors independently associated with electrocardiographic left ventricular hypertrophy (ECG-LVH) in subjects who were normotensive on clinical measurement and had no prior history of hypertension. Methods: This cross-sectional study analyzed cases and controls in the Comprehensive Medical Examination Center of Hallym University Sacred Heart Hospital. Eligible case participants presented ECG-LVH according to the Sokolow-Lyon or Cornell criteria, were normotensive on clinical measurement, and had never received a diagnosis of hypertension. The control group comprised subjects with normal sinus rhythm who were normotensive on clinical measurement with no history of hypertension. Results: A multiple logistic regression model showed male sex, age and systolic blood pressure to be positively related to the presence of ECG-LVH. A positive relation of smoking and regular exercise; an inverse relation of pulse rate to the presence of ECG-LVH were found only in men. An inverse relation of uric acid level was found only in women. Detailed analyses of relatively healthy and young men according to whether or not to exercise regularly showed that positive relations of age and systolic blood pressure; an inverse relation of obesity to the presence of ECG-LVH were apparent in the non-regular exercise group but not in the regular exercise group. In the regular exercise group, only pulse rate showed significant (inverse) association with the presence of ECG-LVH. Conclusion: The varying risk factor profiles associated with ECG-LVH according to sex and the participation in regular exercise may help to elucidate the ECG-LVH in clinical normotensives with no prior history of hypertension.

1 January 2024 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HLHyoeun Lee
Hyoeun Lee
SYSeonghae Yoon
Seonghae Yoon
JCJae-Yong Chung
Jae-Yong Chung
Lee H, et al. Transl Clin Pharmacol. 2024 Sep;32(3):150-158. https://doi.org/10.12793/tcp.2024.32.e14

1 January 2025 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
SJSoo-Min Jung
Soo-Min Jung
SLShi-Hyang Lee
Shi-Hyang Lee
HLHyoeun Lee
Hyoeun Lee
EKEun Na Kim
Eun Na Kim
KBKyun-Seop Bae
Kyun-Seop Bae
Serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels are regulated by growth hormone, nutritional status, and other endocrine factors, and are implicated in aging, metabolic disorders, and malignancies. Establishing appropriate reference ranges for these biomarkers is essential for safety monitoring and pharmacodynamic assessments in clinical trials. Although various detection methods—including enzyme-linked immunosorbent assay, chemiluminescence immunoassay, radioimmunoassay, and immunoradiometric assay (IRMA)—are available, defining reliable reference intervals remains challenging due to variability linked to age, sex, season, and assay methodology. IRMA manufacturers typically provide generalized reference values and recommend that laboratories establish context-specific ranges; however, data from healthy adult populations are limited. We analyzed data from 255 self-reported healthy Korean men aged 19–40 years using the IRMA method and R software. Age-specific reference ranges and standardized centile curves for serum IGF-1 and IGFBP-3 were established. Both biomarkers demonstrated significant seasonal variation, with notable differences observed among spring, autumn, and winter groups. This study presents a method for establishing institution-specific reference ranges and highlights the importance of considering seasonal variations to help reduce unnecessary dropouts during clinical trials.

30 October 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
HLHyoeun Lee
Hyoeun Lee
SYSeok‐Kyu Yoon
Seok‐Kyu Yoon
SJSoo-Min Jung
Soo-Min Jung
MLMoon Hee Lee
Moon Hee Lee
SLShi‐Hyang Lee
Shi‐Hyang Lee
HLHyeong-Seok Lim
Hyeong-Seok Lim
Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker characterized by rapid onset and sustained acid suppression. This study aimed to evaluate the effect of food on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zastaprazan in healthy participants. In this randomized, open‐label, two‐period crossover phase 1 study, 24 healthy participants received a single oral dose of zastaprazan 20 mg under fasted and fed conditions. PK parameters were evaluated using noncompartmental analysis, and PD effects were assessed through continuous intragastric pH monitoring. Under fed conditions, peak exposure (Cmax) decreased (geometric mean ratio [GMR], 0.6997; 90% confidence interval [CI], 0.6292–0.7781), whereas systemic exposure (AUC last ) increased (GMR, 1.3783; 90% CI, 1.2688–1.4973), accompanied by a delayed T max . Despite these PK differences, PD outcomes were comparable between fed and fasted conditions. The percentage of time with intragastric pH ≥ 4 over 24 h was similar under fed and fasted conditions (70.01% vs. 69.19%), with no meaningful differences observed in other pH‐based parameters. Zastaprazan was well tolerated, and no clinically significant safety concerns were identified. Food altered the rate and extent of zastaprazan absorption but did not affect its PD response. These findings indicate that food‐related PK changes do not meaningfully affect PD outcomes and support the administration of zastaprazan without regard to meals. This flexibility may enhance its clinical utility as an acid‐suppressive therapy. Trial Registration: The study was registered at ClinicalTrials.gov (NCT05712681)